Irina Shklyar1, Amy Pasternak2, Kush Kapur2, Basil T Darras2, Seward B Rutkove3. 1. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 2. Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: srutkove@bidmc.harvard.edu.
Abstract
BACKGROUND: Compared with individual parameters, composite biomarkers may provide a more effective means for monitoring disease progression and the effects of therapy in clinical trials than single measures. In this study, we built composite biomarkers for use in Duchenne muscular dystrophy by combining values from two objective measures of disease severity: electrical impedance myography and quantitative ultrasound and evaluating how well they correlated to standard functional measures. METHODS: Using data from an ongoing study of electrical impedance myography and quantitative ultrasound in 31 Duchenne muscular dystrophy and 26 healthy boys aged 2-14 years, we combined data sets by first creating z scores based on the normal subject data and then using simple mathematical operations (addition and multiplication) to create composite measures. These composite scores were then correlated to age and standard measures of function including the 6-minute walk test, the North Star Ambulatory Assessment, and handheld dynamometry. RESULTS: Combining data sets resulted in stronger correlations with all four outcomes than for either electrical impedance myography or quantitative ultrasound alone in six of eight instances. These improvements reached statistical significance (P < 0.05) in several cases. For example, the correlation coefficient for the composite measure with the North Star Ambulatory Assessment was 0.79 but was only 0.66 and 0.67 (respectively) for gray scale level and electrical impedance myography separately. CONCLUSIONS: Arithmetically derived composite scores can provide stronger correlations to functional measures than isolated biomarkers. Longitudinal study of such composite markers in Duchenne muscular dystrophy clinical trials is warranted.
BACKGROUND: Compared with individual parameters, composite biomarkers may provide a more effective means for monitoring disease progression and the effects of therapy in clinical trials than single measures. In this study, we built composite biomarkers for use in Duchenne muscular dystrophy by combining values from two objective measures of disease severity: electrical impedance myography and quantitative ultrasound and evaluating how well they correlated to standard functional measures. METHODS: Using data from an ongoing study of electrical impedance myography and quantitative ultrasound in 31 Duchenne muscular dystrophy and 26 healthy boys aged 2-14 years, we combined data sets by first creating z scores based on the normal subject data and then using simple mathematical operations (addition and multiplication) to create composite measures. These composite scores were then correlated to age and standard measures of function including the 6-minute walk test, the North Star Ambulatory Assessment, and handheld dynamometry. RESULTS: Combining data sets resulted in stronger correlations with all four outcomes than for either electrical impedance myography or quantitative ultrasound alone in six of eight instances. These improvements reached statistical significance (P < 0.05) in several cases. For example, the correlation coefficient for the composite measure with the North Star Ambulatory Assessment was 0.79 but was only 0.66 and 0.67 (respectively) for gray scale level and electrical impedance myography separately. CONCLUSIONS: Arithmetically derived composite scores can provide stronger correlations to functional measures than isolated biomarkers. Longitudinal study of such composite markers in Duchenne muscular dystrophy clinical trials is warranted.
Authors: Jia Li; Tom R Geisbush; Glenn D Rosen; Jennifer Lachey; Aaron Mulivor; Seward B Rutkove Journal: Muscle Nerve Date: 2014-06 Impact factor: 3.217
Authors: Pushpa Narayanaswami; Andrew J Spieker; Phillip Mongiovi; John C Keel; Stefan C Muzin; Seward B Rutkove Journal: Muscle Nerve Date: 2012-08 Impact factor: 3.217
Authors: G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby Journal: Brain Date: 1999-05 Impact factor: 13.501
Authors: Merel Jansen; Nens van Alfen; Maria W G Nijhuis van der Sanden; Johannes P van Dijk; Sigrid Pillen; Imelda J M de Groot Journal: Neuromuscul Disord Date: 2011-11-30 Impact factor: 4.296
Authors: Noel G Faux; Craig W Ritchie; Adam Gunn; Alan Rembach; Andrew Tsatsanis; Justin Bedo; John Harrison; Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Martin Ingelsson; Colin L Masters; Rudolph E Tanzi; Jeffrey L Cummings; Caroline M Herd; Ashley I Bush Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Gary L Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L Miller Journal: Muscle Nerve Date: 2010-04 Impact factor: 3.217
Authors: Benjamin Sanchez; Shama R Iyer; Jia Li; Kush Kapur; Su Xu; Seward B Rutkove; Richard M Lovering Journal: Muscle Nerve Date: 2017-03-24 Impact factor: 3.217
Authors: Kavya S Nair; Donovan J Lott; Sean C Forbes; Alison M Barnard; Rebecca J Willcocks; Claudia R Senesac; Michael J Daniels; Ann T Harrington; Gihan I Tennekoon; Kirsten Zilke; Erika L Finanger; Richard S Finkel; William D Rooney; Glenn A Walter; Krista Vandenborne Journal: J Neuromuscul Dis Date: 2022
Authors: Chady H Hakim; Alex Mijailovic; Thais B Lessa; Joan R Coates; Carmen Shin; Seward B Rutkove; Dongsheng Duan Journal: PLoS One Date: 2017-03-24 Impact factor: 3.240